Related Experiment Video
Updated: Jun 23, 2026
23:56
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Global challenges for clinical pharmacology in the developing world
1Division of Clinical Pharmacology, Stanford University School of Medicine, Stanford, California, USA. blaschke@stanford.edu
Clinical Pharmacology and Therapeutics
|May 20, 2009
Summary
Clinical pharmacologists can improve HIV care delivery in developing nations. However, shortages and emigration of healthcare professionals hinder this progress, necessitating strategic solutions.
Area of Science:
- Global Health
- Pharmacology
- Health Systems Strengthening
Background:
- The escalating burden of Human Immunodeficiency Virus (HIV) care strains healthcare systems in developing countries.
- Existing healthcare infrastructure and personnel face significant challenges in managing the growing demand for HIV treatment and support.
Purpose of the Study:
- To explore the potential role of clinical pharmacologists in enhancing HIV care delivery in resource-limited settings.
- To identify challenges and propose solutions to leverage clinical pharmacology expertise for improved HIV management.
Main Methods:
- This commentary reviews the existing literature and expert opinion on the application of clinical pharmacology principles to HIV care.
- It analyzes the impact of healthcare provider shortages and emigration on care delivery.
- Potential strategies for integrating clinical pharmacologists into HIV care programs are discussed.
Main Results:
- Clinical pharmacologists possess unique skills in regulatory science, rational prescribing, and therapeutics education, which are crucial for effective HIV care.
- A significant shortage of clinical pharmacologists and the emigration of healthcare professionals pose substantial barriers to implementing this approach.
Conclusions:
- Addressing the shortage of clinical pharmacologists and mitigating healthcare provider emigration are critical steps.
- Implementing innovative strategies is essential to harness the expertise of clinical pharmacologists for sustainable and effective HIV care in developing regions.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...